Johnson & Johnson advanced its strategy of moving Erleada (apalutamide) into earlier stages of prostate cancer with a supplemental new drug application submission for treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) announced on 29 April 2019.
J&J Sets Erleada On Real-Time Pathway For Castration-Sensitive Prostate Cancer Claim
Erleada is ninth product known to be using US FDA’s Real-Time Oncology Review pilot program, as shown in our comprehensive chart.
